Future studies should be directed at exploring whether the subgroup of TP53-fusion-positive osteosarcoma comprises a distinct clinicobiological subset of osteosarcoma with respect to metastatic potential, therapeutic responses and immunological control. This evidence concerns the gene TP53 and osteosarcoma.